Qisda : The Company participates in TCI GENE INC.'s private placement of common shares

Close

Today's Information

Provided by: Qisda Corporation
SEQ_NO	2	Date of announcement	2022/05/20	Time of announcement	16:21:40
Subject	The Company participates in TCI GENE INC.'s private placement of common shares
Date of events	2022/05/20	To which item it meets	paragraph 24
Statement	1.Name and nature of the underlying security (if preferred shares, the terms and conditions of issuance shall also be indicated, e.g., dividend yield): TCI GENE INC.'s common shares in a private placement 2.Date of occurrence of the event:2022/05/20 3.No., unit price, and monetary amount of the transaction: Qisda Corporation Number of Shares: 4,720,000 shares Price per Share: NTD$ 115.5 Amount: NTD$ 545,160,000 4.Counterparty to the trade and its relationship to the company (if the trading counterparty is a natural person and not a related party of the company, its name is not required to be disclosed): TCI GENE INC. is not the Company's related party. 5.Where the counterparty to the trade is a related party, an announcement shall also be made of the reason for choosing the related party as trading counterparty and the identity of the previous owner, including its relationship with the company and the trading counterparty, the price of the ownership transfer, and date of transfer:NA 6.Where the owner of the underlying securities within the past five years has been a related party of the company, an announcement shall also include the dates and prices of acquisition and disposal by the related party and its relationship with the company at the time:NA 7.Matters related to the creditor's rights currently being disposed of (including type of collateral of the disposed creditor's rights; if the creditor's rights are creditor's rights over a related party, the name of the related party and the book amount of such creditor's rights currently being disposed of must also be announced):NA 8.Profit (or loss) from the disposal (not applicable in cases of acquisition of securities) (where originally deferred, the status or recognition shall be stated and explained):NA 9.Terms of delivery or payment (including payment period and monetary amount), restrictive covenants in the contract, and other important stipulations: Payment by wired 10.The manner in which the current transaction was decided, the reference basis for the decision on price, and the decision-making unit: decision-making department: Board Resolution Reference Price Basis: According to the price of TCI GENE INC.'s private placement of common shares and the reasonableness opinion issued by the CPA. The decision-making department: The Company's board of directors meeting. 11.Net worth per share of company of the underlying securities acquired or disposed of:17.72 12.The discrepancy between the reference price of private placement company and the transaction amount per share is 20 percent or more: No 13.Current cumulative no., amount, and shareholding ratio of the securities being traded (including the current transaction) as of the date of occurrence and status of any restriction of rights (e.g.,pledges): Qisda Corporation Number of Shares: 4,720,000 shares Amount: NTD$ 545,160,000 Percentage of Shareholding: around 17.84% Restriction on rights: Transferring shares has to follow relevant provisions regarding private placement in Securities and Exchange Act 14.Privately placed securities (including the current transaction) as a percentage of total assets of the company and shareholder's equity of the parent company on the latest financial statements, and the operating capital on the latest financial statements as of the date of occurrence: Current ratio of private placement of securities (Including the current trade approved by the board of directors) to the total assets:6.08% Current ratio of private placement of securities (Including the current trade approved by the board of directors) to the shareholder's equity:16.39% Operating Capital: NTD$ -6,919,740 thousand. Source of funds: Self-owned capital purpose of the acquisition: In order to strengthen the company's biotechnology industry, it has stepped into the field of precision medicine. Through this investment, we will complement each other's resources, expand the biotechnology and medical care business, and provide customers with a wider range of products and services. 15.Broker and broker's fee:No 16.Concrete purpose or use of the acquisition or disposition: In order to strengthen the company's biotechnology industry, it has stepped into the field of precision medicine. Through this investment, we will complement each other's resources, expand the biotechnology and medical care business, and provide customers with a wider range of products and services. 17.Whether the directors expressed any objection to the present transaction:No 18.Whether the trading counterparty is a related party:No 19.Date of approval by board of directors:NA 20.Recognition date by supervisors or approval date by audit committee:NA 21.Whether the CPA issued an opinion on the unreasonableness of the current transaction:No 22.Name of the CPA firm:WeTec International CPAs 23.Name of the CPA:Lai Ming-Yang 24.License no.of the CPA: Taipei City CPA Certificate No. 2123 25.Any other matters that need to be specified: No